Status:
RECRUITING
Trop2-targeting NIR-II Molecular Probe for Guided Identification of Non-Muscle-Invasive Bladder Cancer
Lead Sponsor:
Yunnan Cancer Hospital
Conditions:
Non-Muscle-Invasive Bladder Cancer
Eligibility:
All Genders
18-80 years
Brief Summary
Bladder cancer ranks as the fourth most common malignancy among males the United States . Approximately 75% of patients present with non-muscle-invasive bladder cancer (NMIBC). For the diagnosis and t...
Detailed Description
After patient enrollment, surgical treatment will be administered based on clinical diagnosis and treatment. Following the surgery, excised tissues will undergo incubation with TTP-ICG following this ...
Eligibility Criteria
Inclusion
- Adult patients between 18-80 years of age
- Patients with suspected non-muscle-invasive bladder cancer scheduled to undergo surgical intervention.
- Good operative candidate
- Subject capable of giving informed consent and participating in the process of consent
Exclusion
- Patients unable to participate in the consent process
- Patients had contraindications to surgery, such as serious cardiopulmonary disease, coagulation dysfunction, etc
- Other conditions that the researcher considers inappropriate to participate in the study
Key Trial Info
Start Date :
January 17 2025
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
November 30 2025
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT06972771
Start Date
January 17 2025
End Date
November 30 2025
Last Update
May 30 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Yunnan Cancer Hospital
Kunming, Yunnan, China, 650118